Lilly, AbbVie Lead on M&A and European Approvals

Eli Lilly ($LLY) has announced the acquisition of AtaiBeckley for $2.8 billion, marking a significant entry into the psychedelics drug development space. The deal represents a strategic expansion for $LLY into an emerging therapeutic area, with investor Cathie Wood viewing alternative biotech names in the psychedelics sector as attractive opportunities. Separately, AbbVie ($ABBV) disclosed that it agreed to acquire Apogee Therapeutics for $10.9 billion to strengthen its immunology pipeline. $ABBV stock has delivered 172% returns over five years, though current valuation metrics present a mixed picture with intrinsic value estimates suggesting upside while market multiples indicate the shares screen rich.

AbbVie ($ABBV) announced that the European Commission has approved RINVOQ (upadacitinib) for two new indications in dermatology. The approvals cover treatment of adult and adolescent patients 12 years and older with severe alopecia areata at 15 mg and 30 mg once daily doses, as well as non-segmental vitiligo at 15 mg once daily. RINVOQ is now the first and only systemic medication approved in the European Union for non-segmental vitiligo, the most common form of vitiligo. These European approvals expand the commercial opportunity for $ABBV's key immunology franchise and can support expectations for future cash flows. Meanwhile, biotech company Replimune is engaged in discussions with regulators regarding approval for its first commercial product in combination with Bristol Myers Squibb's ($BMY) Opdivo.

UnitedHealth Group ($UNH) reported second-quarter 2026 results with revenue of $112.03 billion and net income of $5.48 billion, surpassing analyst expectations. The company raised its full-year profit outlook and continues executing share repurchases, highlighting how cost controls and capital returns are shaping its business profile. The earnings beat and outlook increase demonstrate $UNH's ability to manage medical costs while growing its diversified healthcare services businesses. Healthcare stocks have gained 14.3% over the past six months while the S&P 500 was up 6.3%, with companies innovating in drug development and digital health driving sector outperformance.

The global AI in medical coding market is projected to grow from approximately $3 billion in 2025 to $3.4 billion in 2026, reaching $10.6 billion by 2035 at a compound annual growth rate of 13.5%. Key market participants include 3M Company and Optum Inc., a UnitedHealth ($UNH) subsidiary, positioning the managed care giant to benefit from technology-driven efficiency gains in healthcare administration. Separately, the global precision diagnostics and medicine market is expected to expand from approximately $147.23 billion in 2025 to $159.66 billion in 2026, reaching $345.75 billion by 2035 at an 8.91% CAGR, with Thermo Fisher Scientific ($TMO) among the leading players.

Amgen ($AMGN) will report second-quarter 2026 financial results on August 4, 2026, after the close of U.S. financial markets, followed by a conference call at 4:30 p.m. ET with chairman and CEO Robert A. Bradway and senior management. AbbVie ($ABBV) faces an upcoming earnings report after the stock climbed 15% from its June 23 breakout above the 230.47 buy point from a cup-with-handle base, following the Apogee Therapeutics acquisition announcement that drove shares more than 6% higher. Johnson & Johnson ($JNJ) has delivered strong Q2 earnings with record results and raised guidance, driven by its oncology engine and steady performance across business segments.